François Barde

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Interstitial Lung Disease

Systemic Sclerosis

Regulatory T Cells

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

François Barde, Roberta Lorenzon, Eric Vicaut, Sébastien Rivière, Patrice Cacoub, Carlotta Cacciatore, Michelle Rosenzwajg, Anne Daguenel-Nguyen, Olivier Fain, David Klatzmann, Arsenne Mekinian
Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study. RMD open 10 (2) (2024)
François Barde, Roberta Lorenzon, Eric Vicaut, Sébastien Rivière, Patrice Cacoub, Carlotta Cacciatore, Michelle Rosenzwajg, Anne Daguenel-Nguyen, Olivier Fain, David Klatzmann, Arsenne Mekinian
Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study. RMD open 10 (2) (2024)
François Barde, Roberta Lorenzon, Eric Vicaut, Sébastien Rivière, Patrice Cacoub, Carlotta Cacciatore, Michelle Rosenzwajg, Anne Daguenel-Nguyen, Olivier Fain, David Klatzmann, Arsenne Mekinian
Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study. RMD open 10 (2) (2024)
François Barde, Roberta Lorenzon, Eric Vicaut, Sébastien Rivière, Patrice Cacoub, Carlotta Cacciatore, Michelle Rosenzwajg, Anne Daguenel-Nguyen, Olivier Fain, David Klatzmann, Arsenne Mekinian
Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study. RMD open 10 (2) (2024)
François Barde, Roberta Lorenzon, Eric Vicaut, Sébastien Rivière, Patrice Cacoub, Carlotta Cacciatore, Michelle Rosenzwajg, Anne Daguenel-Nguyen, Olivier Fain, David Klatzmann, Arsenne Mekinian
Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study. RMD open 10 (2) (2024)